MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2024 International Congress

    Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

    Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…
  • 2024 International Congress

    Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity

    A. Bezrukova, K. Basharova, G. Baydakova, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…
  • 2024 International Congress

    Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data

    R. Joseph, J. Qian, H. Cummings, Y. Chen, S. Tewari, M. Soileau (Columbus, USA)

    Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…
  • 2024 International Congress

    Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose

    R. Kleiman, J. Mickelson, R. Sanwo, C. Edwards, S. Fisher, H. Visser (South Gate, USA)

    Objective: To assess the cardiac safety of a single supratherapeutic dose of carbidopa in healthy adults. Background: Carbidopa has been approved for use in combination…
  • 2024 International Congress

    Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.

    F. Reis Rodrigues, E. Pasqualotto, G. Ribeiro, J. M. Couto, E. Bayram, M. Ushe, D. Di Luca (Vicosa, Brazil)

    Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…
  • 2024 International Congress

    Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.

    D. Rivero-Rodríguez, M. Morales-Casado, G. Tabar-Comellas, A. Diezma-Martín, P. Quintana-Castro, M. Ennazeh, N. López-Ariztegui (Toledo, Spain)

    Objective: To determine the clinical characteristics associated with early withdrawal of Levodopa-Carbidopa Intestinal Gel infusion (LCIG) in patients with advanced Parkinson´s Disease (APD) Background: LCIG…
  • 2024 International Congress

    Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine

    S. Saaf, S. Lhassani, Z. El Yacoubi, Y. Mimouni, M. El Azhari, L. Kazzoul, J. Aasfara, H. Ouhabi, A. Hazim (Casablanca, Morocco)

    Objective: To report the case of a pharmaco-induced oro-facial dyskinesia and akathisia. Background: Dyskinesia is a hyperkinetic, disorganized, involuntary movement disorder that can either be…
  • 2024 International Congress

    Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion

    M. Minar, I. Straka, Z. Kosutzka, Z. Andre (Bratislava, Slovakia)

    Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…
  • 2024 International Congress

    Changes in Parkinson’s Disease and Parkinsonian Syndromes A Comparative Retrospective Study in Kyrgyzstan

    S. Medetbekova, B. Nurbekova (Bishkek, Kyrgyzstan)

    Objective: This study compares Parkinson's disease (PD) and parkinsonian syndromes (PS) in patients at a Kyrgyzstan university hospital. It analyzes data from 2016-2017 [1] and…
  • 2024 International Congress

    Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology

    P. Lewitt, G. Stebbins, K. Christensen, M. Thomsen, R. Tan, A. Pretorius (Detroit, USA)

    Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…
  • 1
  • 2
  • 3
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley